Abciximab-induced delayed profound thrombocytopaenia
Authors:
- 2 June 2017
- journal article
- case report
- Published by BMJ in BMJ Case Reports
- Vol. 2017
Abstract
Abciximab, the first approved glycoprotein (GP IIb/IIIa) inhibitor, is being widely used during acute coronary syndromes and offers the promising approach to antithrombotic therapy. We present a case of a young woman who initially received abciximab infusion for undergoing percutaneous coronary intervention of left anterior descending artery and was eventually diagnosed with abciximab-induced delayed thrombocytopaenia. This case outlines the importance of close follow-up of these patients to prevent serious adverse events.Keywords
This publication has 13 references indexed in Scilit:
- How abciximab might be clinically usefulInternational Journal of Cardiology, 2016
- Delayed, severe thrombocytemia after abciximab infusion for primary angioplasty in acute coronary syndromes: Moving between systemic bleeding and stent thrombosisPlatelets, 2014
- Approach to the Diagnosis and Management of Drug-Induced Immune ThrombocytopeniaTransfusion Medicine Reviews, 2013
- Drug-Induced Immune ThrombocytopeniaNew England Journal of Medicine, 2007
- Immune Thrombocytopenia Caused by Glycoprotein IIb/IIIa InhibitorsChest, 2005
- Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drugJournal of Thrombosis and Haemostasis, 2004
- A Practical Approach to the Diagnosis and Management of Thrombocytopenia Associated with Glycoprotein IIb/IIIa Receptor InhibitorsJournal of Thrombosis and Thrombolysis, 2000
- Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.Journal of Clinical Investigation, 1997
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Integrins: A family of cell surface receptorsCell, 1987